Epizyme partners with GlaxoSmithKline to discover, develop and commercialize small molecule therapeutics targeting histone methyltransferases for cancer and other diseases

Epizyme Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

GlaxoSmithKline plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced